We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tissue Regenix Group Plc | LSE:TRX | London | Ordinary Share | GB00BNTXR104 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 61.50 | 61.00 | 62.00 | 61.50 | 60.80 | 61.50 | 1,588 | 08:00:27 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 29.49M | -302k | -0.0043 | -143.02 | 43.4M |
TIDMTRX
RNS Number : 5173K
Tissue Regenix Group PLC
05 January 2021
Tissue Regenix Group plc
Confirmation of Board appointments
Leeds, 5 January 2021 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or the "Group") the regenerative medical devices company, announces that, following the Group's announcement on 4 December 2020, Brian Phillips and Trevor Phillips have been appointed to the Board as independent Non-Executive Directors of Tissue Regenix.
Brian Phillips is now Chair of the Audit Committee and Trevor Phillips is Chair of the Remuneration Committee.
For more Information:
Tissue Regenix Group plc Tel: 0330 430 3052 Caitlin Pearson Head of Communications ------------------------------------------ -------------------- Stifel Nicolaus Europe Limited (Nominated Tel: 0207 710 7600 Adviser and Broker) Ben Maddison / Alex Price ------------------------------------------ --------------------
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL(R)') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.
In August 2017 Tissue Regenix acquired CellRight Technologies(R), a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.
Regulatory disclosures
Trevor Michael Phillips, 59, has been a director or partner of the following companies or partnerships during the past five years:
Current directorships/partnerships Directorships/partnerships within the last 5 years Prostratex Limited Vectura Group Investments Limited NEPeSMO Limited hVIVO Limited hVIVO Services Limited Open Orphan plc Morvus Technology Limited Prep Biopharm Limited Imutex Limited Quadrant Drug Delivery Limited QDose Limited Quadrant Technologies Limited Quadrant Healthcare Limited Quadrant Holdings Cambridge Limited Quadrant Healthcare (UK) Limited Quadrant Trustee Limited Quadrant Bioresources Limited Protosome Limited Andaris Group Limited Andaris (DDS) Limited Microshot Limited Innovata Biomed Limited Innovata Limited Vectura Group Services Limited
Trevor holds no shares in Tissue Regenix plc and there are no further disclosures required in accordance with AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.
George Brian Phillips, 60, has been a director or partner of the following companies or partnerships during the past five years:
Current directorships/partnerships Directorships/partnerships within the last 5 years NAHL Group plc Dig Space Limited Muirfield Finance Limited Tanygraig Limited Muirfield Midco Limited Preoday Limited Muirfield Holdco Limited Motocaddy Holdings Limited Motocaddy Limited Ethos Partners LLP Imbiba Capital Limited Imbiba (FP) LLP Imbiba (GP) LLP Imbiba Growth LLP Purple Dragon (Holdings) Limited Qikserve Limited E&P Data Licensing Limited The Jane Bubear Sport Foundation
Brian Phillips was a director of Valiant Sport Holdings Limited at the time it was placed into voluntary liquidation by members and creditors on 2 April 2013. The company was dissolved on 5 September 2014. There were no secured or preferential creditors. Unsecured creditors holding approximately GBP2.65m in aggregate received 0.7124p in pound.
Brian holds no shares in Tissue Regenix plc and there are no further disclosures required in accordance with AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
BOAFLFFTLEISIIL
(END) Dow Jones Newswires
January 05, 2021 02:00 ET (07:00 GMT)
1 Year Tissue Regenix Chart |
1 Month Tissue Regenix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions